KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Gross Profit (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Gross Profit for 7 consecutive years, with $46.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 33.99% year-over-year to $46.0 million, compared with a TTM value of $176.8 million through Sep 2025, down 26.65%, and an annual FY2024 reading of $263.7 million, up 260.92% over the prior year.
  • Gross Profit was $46.0 million for Q3 2025 at Esperion Therapeutics, down from $53.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $127.7 million in Q1 2024 and bottomed at $6.2 million in Q1 2021.
  • Average Gross Profit over 5 years is $30.7 million, with a median of $20.6 million recorded in 2023.
  • The sharpest move saw Gross Profit tumbled 81.66% in 2021, then skyrocketed 907.02% in 2024.
  • Year by year, Gross Profit stood at $10.3 million in 2021, then soared by 41.95% to $14.7 million in 2022, then surged by 41.89% to $20.8 million in 2023, then skyrocketed by 109.07% to $43.5 million in 2024, then grew by 5.84% to $46.0 million in 2025.
  • Business Quant data shows Gross Profit for ESPR at $46.0 million in Q3 2025, $53.8 million in Q2 2025, and $33.5 million in Q1 2025.